P3.02c-094 Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases
Diego Cortinovis(Azienda Ospedaliera San Gerardo), Francesco Cognetti(Apple (Israel)), Davide Tassinari(University of Bologna), Rita Chiari(Azienda Ospedaliera di Perugia), Francesco Gelsomino(Azienda USL di Bologna), Francesco Grossi(University of Insubria), Claudia Proto(Fondazione IRCCS Istituto Nazionale dei Tumori), Cristina Noberasco(European Institute of Oncology), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Héctor Soto Parrà, Valeria Albanese(Ospedale Vincenzo Cervello), Marina Gilli(Ospedale Monaldi), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Annamaria Catino(Istituto Tumori Bari), Giovanni Maria Fadda(Università Cattolica del Sacro Cuore), Lucia Bonomi, Maria Rita Migliorino(Carlo Forlanini Hospital), Giovanna Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 8
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|454